News Release

Researchers create a strong new molecule in the fight against AIDS

Peer-Reviewed Publication

American Chemical Society

Integrase inhibitor may prevent HIV from taking over healthy cells

Researchers have created a new molecule that appears to survive in cells longer than existing treatments to combat the virus that leads to AIDS, according to a new study reported in the June 21 edition of the peer-reviewed Journal of the American Chemical Society, published by the world's largest scientific society.

The new molecule, called a dinucleotide, has been created in the laboratory of Vasu Nair, Ph.D. at the University of Iowa, using complex molecular engineering techniques. No human or animal testing has been done and much more testing is necessary before the compound can become a drug, he noted.

Drugs to arrest the effects of other viral enzymes that lead to HIV are currently in clinical use to stop the infectious chemical chain reaction. The virus, however, often overcomes these drugs -- including well-known AZT -- through development of resistance. Promising preliminary lab results show that the new integrase inhibitor molecule may possess the ability to withstand the body's attempts to block its actions, said Nair, who was lead author of the study.

More than 40 million people worldwide are infected with the human immunodeficiency virus, referred to as HIV, which leads to AIDS. Current drug treatments face ongoing problems with drug resistance and toxicity, making the current study relevant to the next generation of AIDS medical treatments.

The compound is designed to stop HIV infection by preventing the virus from spreading to non-infected human cells. Called an HIV integrase inhibitor, the potential drug stops a key step that allows the virus to infect people, Nair said. The work was done in collaboration with the National Institutes of Health.

"I feel excited about this as a basic advancement in the science of inhibitors of this virus," Nair said. "Most therapeutic advances start this way, with scientific discoveries such as this."

HIV infection is a multi-step process, where the virus penetrates the body's cells and begins to replicate itself. The virus uses its own enzymes and reproduces itself through the body's own biochemistry.

An early major step involves a viral enzyme called reverse transcriptase that creates the DNA of the virus. The next step involves the HIV integrase enzyme, which allows the virus to take over normal human cells by "integrating" the viral DNA into the cells. Once integrated, the virus can reproduce itself. A subsequent third enzyme, protease, allows the virus to continue to replicate itself and spread the infection from cell to cell.

Development of a potential solution to stopping integrase, which inserts viral DNA into healthy cells, would allow doctors another chance to stop the onset of AIDS if the other drugs are unsuccessful. It is not a vaccine for the virus, but ideally it may represent another approach to combating the spread of the disease, Nair said.

"The integrase step is the most critical step in my point of view, because this is where the (viral) invasion is complete," Nair said. "From a scientific point of view, this is the step in which the real damage is done."

###

6/19/00 #12794

Dr. Vasu Nair, Distinguished Professor of Chemistry, Department of Chemistry, University of Iowa

The on-line version of the research paper cited above is available on the American Chemical Society's ASAP (As Soon As Publishable) Web site. Journalists desiring full access to papers at the ASAP site must submit a written request to the ACS Department of News and Information or send an e-mail to newsroom@acs.org.

The on-line version of the research paper cited above was initially published June 3 on the journal's Web site. The research was funded by the National Institutes of Health.

A nonprofit organization with a membership of 161,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio. (http://www.acs.org)


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.